Literature DB >> 28217435

A rare fungal infection: Phaehyphomycosis due to Veronaea botryosa and review of literature.

Anne Welfringer1, Valérie Vuong1, Nicolas Argy2, Christian Chochillon2, Lydia Deschamps3, Guillaume Rollin4, Stanislas Harent4, Véronique Joly4, William Vindrios4, Vincent Descamps1.   

Abstract

We report a rare case of phaehyphomycosis in a 71-year-old heart transplant recipient Togo native patient. Four months after the transplant, he presented painless nodules on the right heel with superficial ulceration. The polyphasic identification uncovered a rare cause of phaehyphomycose: V. botryosa. The treatment combined surgical excision of the lesions and anti-fungal therapy with posaconazole. We discussed eleven reported cases in literature since 1990.

Entities:  

Keywords:  Heart transplant recipient; Immunosuppression; Phaeohyphomycosis; V. botryosa

Year:  2017        PMID: 28217435      PMCID: PMC5300299          DOI: 10.1016/j.mmcr.2017.02.001

Source DB:  PubMed          Journal:  Med Mycol Case Rep        ISSN: 2211-7539


Introduction

Infectious complications, especially fungal, are common in transplant recipients due to the underlying immunosuppression. We report a rare case of phaehyphomycosis Veronaea (V.) botryosa in a heart transplant recipient. The originality of this phaehyphomycosis is the rarity of the species identified. In the literature, 11 other cases of V. botryosa-induced cutaneous phaeohyphomycosis have been reported since 1990 including 3 cases in transplant recipients. This case highlighted the importance of careful research of fungal infection in immunocompromised transplant recipients and monitoring of the immunosuppressive regimen.

Case

A 71 year old native Togo patient, who has been living in France since 1970 and has not been back to Africa for 20 years, also a heart transplant recipient, was hospitalized for nodules on his right heel. The nodules were painless and slowly progressive with superficial ulceration (1A and 1B). His significant medical history included hypertension, insulin-dependent diabetes mellitus, and ventricular tachycardia with implantable defibrillator. He had a history of hypertrophic cardiomyopathy that required a heart transplantation on May 2014 (day 1), and was complicated by several bacterial infections (Enterobacter cloacae, Enterococcus faecalis, Pseudomonas aeruginosa), fungal infections (Fusarium sp. ascites), and a postoperative CMV reactivation. His immunosuppressive treatment included mycophenolate mofetil 500 mg×2/d, corticosteroids 10 mg/d, and cyclosporine 125 mg×2/d, (concentration of 197 ng/ml target 200–250). The skin nodules developed a few months after transplantation, on August 2014. In December 2014 (day 210), histological analysis of skin biopsy demonstrated multinucleated giant cells, epidermal hyperplasia, abscesses with neutrophil infiltrates (1C) and pigmented conidia with positive Grocott staining (1D). The isolate was sent to the National Reference Center for Invasive Mycoses and Antifungals (NRCMA), Institut Pasteur, Paris, for speciation. The microscopic examination of a velvety blackish-brown colony on 2% malt agar (MEA), revealed straight to flexuous, smooth-walled melanized conidiophores (2A and 2B). Conidiogenous cells were mostly terminal, bearing 1-septate smooth-walled cylindrical conidia truncated at the base. On the basis of its morphological features, the filamentous fungus was identified as Veronaea botryosa. Molecular confirmation was ascertained by the amplification and sequencing of the ITS1-5.8S-ITS2 region of the ribosomal DNA [1]. Comparison of the nucleotide sequence of the isolate (623 bp) with GenBank database showed a 99.8% identity (623/622) with V. botryosa type strain CBS 254.57 (GenBank NR_103593.1). Due to the immunodeficiency of the patient, a staging was performed (PET scan and brain imaging) which returned normal. Lymphopenia (210/mm3) was noted in the blood test. The treatment included surgical excision of the lesions and anti-fungal therapy with posaconazole 400 mg twice a day for 3 months. The evolution of the lesions was favorable, but a few months later (day 330), the patient died from septic shock (Klebsiella pneumonia and Escherichia coli septicemia) (Fig. 1, Fig. 2).
Fig. 1

painless nodules, with superficial ulceration (1A and 1B). (1C and 1D) original magnification ×400 Histological analysis of skin biopsy demonstrated multinucleated giant cells containing pigmented spores, (hematoxylin eosin stain) (1C) Grocott staining showed numerous spores (1D).

Fig. 2

Culture on Sabouraud chloramphenicol at 27 °C (2A). Micromorphology of conidiophores, conidiogenous cells and conidia of V. botryose (2B).

painless nodules, with superficial ulceration (1A and 1B). (1C and 1D) original magnification ×400 Histological analysis of skin biopsy demonstrated multinucleated giant cells containing pigmented spores, (hematoxylin eosin stain) (1C) Grocott staining showed numerous spores (1D). Culture on Sabouraud chloramphenicol at 27 °C (2A). Micromorphology of conidiophores, conidiogenous cells and conidia of V. botryose (2B).

Discussion

Phaehyphomycosis is defined by the presence of melanized yeast-like cells or hyphae in tissues. Patients diagnosed with phaeohyphomycosis are often immunocompromised (diabetics, transplant recipients, patients on immunosuppressive drugs or steroids). These fungi induce subcutaneous and systemic opportunistic and cosmopolitan infections [2]. They are saprophyte of plants, water, and earth. Their transmission mode is land-based, through contaminated water or vegetable items. The melanin present in the cell wall is a known virulence factor. The physiopathology of the infection remains unclear, but some authors speculate that the organism is acquired previously, remained quiescent, and is reactivated due to immunosuppression [3]. [4], The uniqueness of this phaehyphomycosis case is that the species found is extremely rare. To date, only 11 cases of V. botryosa-induced cutaneous phaeohyphomycosis have been reported since 1990. We report here the main characteristics of these patients (Table 1): most patients were natives from Asia, the mean (age: 51,7 years old, and most of them were males (8 men/12 cases with our case). This is the third reported case of V. botryosa infection in a transplant-recipient. The clinical presentation was papulo-nodules or ulcerations, mainly on the lower limbs. All patients were treated by anti-fungals and four with surgery leading to a favorable outcome with resolution of the lesions for 7 patients.
Table 1

Reported cases of V. botryosa induced cutaneous phaeohyphomycosis.

Case (ref.)Yearsage/SexCountry originImmunosuppression/comorbiditiesSoil or plant exposureClinical presentationTreatmentFollow-up
1/[6]199024MChinaNAFarmerBlack, verrucous nodules and cysts on back of hands, cheeks, and forearmAmB and lesional excision without efficacy;NA
2/[7]199528FLibyaNANANodular-ulceronodular lesions on thumb and fifth finger, upper limb, nasal mucosa, and palateNANA
3/[8]199837MPhilippinesNANoerythematous, pruritic papules on the right deltoid and left shinItracozazoleHealing
4/[3]199957MFranceLiver transplant: appearance of lesions 11 weeks after transplantationNoMultiple painless dermal nodules that coalesced and spontaneously yielded pusItraconazoleHealing
5/[9]200381MTaiwanNo/Chronic renale failureFarmerSwelling plaque, papulonodules on Left leg and dorsal footDebridement and ItraconazoleHealing
6/[10]200312MChinaUnknownNoDisseminated nodular lesions on face, upper limbs, legs, scrotum, and buttocksHerbal medication thermotherapy, local AmB injection; Terbinafine, itraconazoleNo effect
7/[4]200462MUSAHeart transplantNoArea of chronic induration and tenderness over the dorsum of the right handItraconazole and Vorinonazole (gastrointestinal complaints) and incisionHealing
8/[11]200676MTaiwanNoFarmerCrusted nodules and plaques. Right forearm and knee, left upper limbItraconazole/amBNo effect
9/[12]200765FJapanVHCFarmerA erythematous, slightly scaly, indurated plaque on the dorsum of the left wrist of more than 3 years’ durationSurgical excisionHealing
10/[13]201016FChinaNoNocrusted, verrucous lesions, initially on the left ear and later on the left buttockItraconazoleHealing
within 2–5 months of receiving an ear piercing
11/[14]201232FMexicoaggravated by pregnancyNoChronic dermatosis which startedPosaconazoleImprovement of the lesions
10 years earlier with multiple Exophytic, multilobulated, soft, and penduculated or sessile neoformations of diverse sizes from 2 to 10 cm in diameter, which became verrucose and increased in size.
12/[15]: Case reported in this article201571MFranceHeart Transplant, four months after the transplantNOPainless, slowly progressive on the leg with superficial ulcerationExcision and PosaconazoleDeath
Reported cases of V. botryosa induced cutaneous phaeohyphomycosis. V. botryosa can induce both chromoblastomycosis (chronic disease of the skin and subcutaneous tissues in tropical regions characterized by the presence of fumagoid cells and phaeohyphomycosis). The clinical presentation of phaehyphomycosis is polymorphic (only skin involvement, systemic, superficial, or deep infection). It requires both histopathological and mycological analysis. Histological diagnostic criteria include the presence of brown hyphae, septate vesicular thickened wall to dark brown accompanied by yeast-like elements poorly systematized in an inflammatory granuloma. The cell wall is pigmented and stained by Gomori Grocott. Histology displays a cystic abscess with granulomatous reaction. Identification of the species involved is essential since many different species can be responsible for phaeohyphomycosis. Lack of sporulation for the isolate prevented antifungal susceptibility testing. However, previous studies have shown that the species usually exhibits high minimal inhibitory concentrations (MIC) of amphotericin B, terbinafine, voriconazole and echinocandins with lower MICs of itraconazole and posaconazole [5]. The patient was thus prescribed posaconazole together with surgical resection of the lesion. Most of the cases reported were only prescribed antifungal drugs. Phaeohyphomycosis should be kept in mind in transplant recipients.

Conflict of Interest

There are none.
  10 in total

1.  Cutaneous phaeohyphomycosis caused by Veronaea bothryosa in a liver transplant recipient successfully treated with itraconazole.

Authors:  F Foulet; C Duvoux; C de Bièvre; C Hézode; S Bretagne
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

2.  Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea.

Authors:  E Alvarez; D Garcia-Hermoso; D A Sutton; J F Cano; A M Stchigel; D Hoinard; A W Fothergill; M G Rinaldi; F Dromer; J Guarro
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

3.  Cutaneous phaeohyphomycosis caused by Veronaea botryosa observed as sclerotic cells in tissue.

Authors:  Yukiko Kondo; Masataro Hiruma; Akiko Matsushita; Shoichi Matsuba; Kazuko Nishimura; Kenji Takamori
Journal:  Int J Dermatol       Date:  2007-06       Impact factor: 2.736

4.  Severe disseminated phaeohyphomycosis in an immunocompetent patient caused by Veronaea botryosa.

Authors:  Alexandro Bonifaz; Mehrnaz Mohammad Davoudi; G S de Hoog; Carmen Padilla-Desgarennes; Denisse Vázquez-González; Gisela Navarrete; Jacques F Meis; Hamid Badali
Journal:  Mycopathologia       Date:  2013-03-08       Impact factor: 2.574

5.  Phaehyphomycosis caused by Veronea bothryosa.

Authors:  A Ayadi; M R Huerre; C de Bievre
Journal:  Lancet       Date:  1995 Dec 23-30       Impact factor: 79.321

6.  A rare complication of ear piercing: a case of subcutaneous phaeohyphomycosis caused by Veronaea botryosa in China.

Authors:  H Sang; X E Zheng; Q T Kong; W Q Zhou; W He; G X Lv; Y N Shen; W D Liu
Journal:  Med Mycol       Date:  2010-09-21       Impact factor: 4.076

7.  Cutaneous phaeohyphomycosis caused by an Itraconazole and Amphoterecin B resistant strain of Veronaeae botryosa.

Authors:  Yu-Ting Chen; Hao-Chiung Lin; Chieh-Chen Huang; Yuan-Hsin Lo
Journal:  Int J Dermatol       Date:  2006-04       Impact factor: 2.736

8.  Subcutaneous phaeohyphomycosis caused by Veronaea botryosa in the People's Republic of China.

Authors:  A Matsushita; L Jilong; M Hiruma; M Kobayashi; T Matsumoto; H Ogawa; A A Padhye
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 9.  First U.S. report of subcutaneous phaeohyphomycosis caused by Veronaea botryosa in a heart transplant recipient and review of the literature.

Authors:  D A Sutton; M G Rinaldi; M Kielhofner
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility.

Authors:  Hamid Badali; Seyed Amir Yazdanparast; Alexandro Bonifaz; Bita Mousavi; G Sybren de Hoog; Corné H W Klaassen; Jacques F Meis
Journal:  Mycopathologia       Date:  2013-03-06       Impact factor: 2.574

  10 in total
  3 in total

1.  Experimental Infection of Mice with Veronaea botryosa as a Model for Human Phaeohyphomycosis.

Authors:  Rachel D Brownlee; Denise M Imai; Denver J Coleman; Amir Ardeshir; Samah M R Abdelrazek; Esteban Soto
Journal:  Comp Med       Date:  2019-08-06       Impact factor: 0.982

2.  First recorded outbreak of Veronaea botryosa in North American amphibians: Clinicopathologic features of a rare cause of phaeohyphomycosis in captive White's tree frogs (Litoria caerulea).

Authors:  Treana Mayer; Alexandra E Moskaluk; Jonathan E Kolby; Michael Russell; Paula Schaffer; Anna C Fagre
Journal:  Med Mycol Case Rep       Date:  2022-09-23

3.  Environmental prospecting of black yeast-like agents of human disease using culture-independent methodology.

Authors:  Flávia de Fátima Costa; Nickolas Menezes da Silva; Morgana Ferreira Voidaleski; Vinicius Almir Weiss; Leandro Ferreira Moreno; Gabriela Xavier Schneider; Mohammad J Najafzadeh; Jiufeng Sun; Renata Rodrigues Gomes; Roberto Tadeu Raittz; Mauro Antonio Alves Castro; Graciela Bolzón Inez de Muniz; G Sybren de Hoog; Vania Aparecida Vicente
Journal:  Sci Rep       Date:  2020-08-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.